Clinical trial NCT03229291: A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects
Official title: A Phase 1, Single-Center, Randomized, Single-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Tendinopathy
Keywords: SM04755
topical
Samumed
Wnt inhibitor
Lead sponsor: Biosplice Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2017-07-25
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a single-center, randomized, single-blind, placebo-controlled, multiple ascending dose study of SM04755 solution applied topically once daily for 14 days to intact skin overlying the inner thigh of healthy subjects at an estimated body surface area (BSA) of 80 cm\^2. Dosing cohorts will consist of 8 subjects who will be randomized 3:1 (SM04755:placebo).


Eligibility criteria: Inclusion Criteria:

* Body mass index of 18 to 30 kg/m\^2 at study start
* Subject must have read and understood the informed consent form, and must have signed it prior to any study-related procedure being performed
* Willingness to comply with all scheduled study visits, laboratory tests, contraception requirements and other study procedures
* Appropriate skin characteristics at site of application (inner thigh) (for example, consistent pigmentation, no tattoos, no scarring or noted injury, no varicose veins or structural repair)
* Willing to avoid extensive sun exposure, phototherapy, or use of a tanning salon for the duration of the study

Exclusion Criteria:

* Women who are pregnant or lactating
* Women of childbearing potential who are sexually active and are not willing to use a highly effective method of birth control during the study period that includes double barrier, intrauterine device (IUD), or hormonal contraceptive combined with single barrier, or abstinence
* Males who are sexually active and not willing to use a condom, and have a partner who is capable of becoming pregnant, if neither has had surgery to become sterilized, and/or who are not willing to use double barrier or whose partner is not using a highly effective method of birth control (e.g., IUD or hormonal contraception combined with single barrier).
* History of, or current, skin disease (for example, psoriasis, atopic dermatitis, seborrheic dermatitis, and skin cancer)
* History of, or current, skin damage at the treatment site (inner thigh) (for example, cuts, abrasion, sunburn, sun-damage, or scarring)
* Phototherapy or use of a tanning salon 2 weeks prior to study start until end of the study (Day 28)
* History of, or current, allergy to investigational product/placebo ingredients
* Known allergy to adhesive tape
* Current evidence of malignancy or history of malignancy within the last 5 years prior to study start; prior history of in situ cancer or basal or squamous cell skin cancer, completely excised, is allowed
* Treatment with an investigational product within 12 weeks prior to study start; the last date of participation in the trial, not the last date of receipt of investigational product, must be at least 12 weeks prior to study start
* Use of any prescription or nonprescription drugs \[except birth control or hormone replacement therapy (HRT)\], topical skin treatments on the application site (inner thigh), vitamins, grapefruit/grapefruit juice, or dietary or herbal supplements within 14 days prior to study start
* Blood donation of ≥ 1 pint (473 mL) within 56 days prior to study start or unwilling to refrain from blood donation for the duration of the study
* Plasma or platelet donation within 14 days prior to study start or unwilling to refrain from plasma or platelet donation for the duration of the study
* Unwilling to refrain from sperm donation for the duration of the study and until 90 days after dose administration
* Prior or current latent or active tuberculosis (TB) or nontuberculous mycobacteria infection.
* Evidence of active infection or illness involving fever within 7 days prior to study start
* Occurrence of serious illness requiring hospitalization within 6 months prior to study start
* Regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces \[150 mL\] of wine or 12 ounces \[360 mL\] of beer or 1.5 ounces \[45 mL\] of hard liquor) within 6 months prior to study start
* Use of tobacco- or nicotine-containing products (cigarettes, pipe, cigar, chewing tobacco or nicotine gum, lozenges or patches) within 30 days prior to study start
* A history of abuse of prescription or illicit drugs within 6 months prior to study start
* Marijuana use within 28 days prior to study start
* Previous treatment with SM04755
* Subjects who have a current or pending disability claim, workers' compensation, or litigation(s) that may compromise response to treatment
* Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the investigative site, or are directly affiliated with the study at the investigative site
* Subjects employed by Samumed, LLC, or any of its affiliates or development partners (that is, an employee, temporary contract worker, or designee) responsible for the conduct of the study

Primary outcomes:
measure: Incidence of adverse events (AEs)
timeFrame: Day 28
measure: Incidence of clinical laboratory abnormalities
timeFrame: Day 28
measure: Change in vital signs: blood pressure
timeFrame: Baseline and Day 28
measure: Change in vital signs: temperature
timeFrame: Baseline and Day 28
measure: Change in vital signs: respiratory rate
timeFrame: Baseline and Day 28
measure: Change in vital signs: pulse rate
timeFrame: Baseline and Day 28
measure: Change in electrocardiogram (ECG) parameters
timeFrame: Baseline and Day 28
measure: Plasma pharmacokinetics (PK): Cmax
timeFrame: Day 1
measure: Plasma pharmacokinetics (PK):tmax
timeFrame: Day 1
measure: Plasma pharmacokinetics (PK): AUC
timeFrame: Day 1
measure: Plasma pharmacokinetics (PK):half-life
timeFrame: Day 1
measure: Plasma pharmacokinetics (PK):Cmax
timeFrame: Day 14
measure: Plasma pharmacokinetics (PK):tmax
timeFrame: Day 14
measure: Plasma pharmacokinetics (PK): AUC
timeFrame: Day 14
measure: Plasma pharmacokinetics (PK):half-life
timeFrame: Day 14
measure: Change in skin score assessment: erythema
timeFrame: Baseline and Day 28
measure: Change in skin score assessment: scaling
timeFrame: Baseline and Day 28
measure: Change in skin score assessment: pruritus/itching
timeFrame: Baseline and Day 28
measure: Change in skin score assessment: burning/stinging
timeFrame: Baseline and Day 28
Secondary outcomes:
measure: Incidence of AEs relative to exposure
timeFrame: Day 28
Other outcomes:
Locations:
city: Tempe
country: United States
facility: Research Site
state: Arizona
Study officials:
affiliation: Biosplice Therapeutics, Inc.
name: Yusuf Yazici, M.D.
role: STUDY_DIRECTOR
References: